Combination treatment before surgery for unresectable esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of treatments given before surgery to shrink tumors in patients with esophageal cancer that is considered too advanced for immediate surgery. The goal is to make surgery possible and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma, confirmed by biopsy.
- Your cancer is in the thoracic (chest) part of the esophagus and has not spread to distant organs.
- You have not had any previous cancer treatment like surgery, radiation, chemotherapy, or immunotherapy.
- Your cancer is considered borderline unresectable (not removable by surgery right now) but might be made removable with treatment.
- You are in good general health with a performance status of 70 or higher on the Karnofsky scale.
- Your blood counts and organ function (kidney, liver) are within normal limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving an immunotherapy drug called tislelizumab before surgery helps shrink esophageal cancer and improve outcomes. It is for people newly diagnosed with early-stage squamous cell esophageal cancer that can be removed surgically.
This trial tests whether combining the immunotherapy drug tislelizumab with chemotherapy before and after surgery helps treat esophageal squamous cell cancer better than just surgery alone. It aims to shrink the tumor before surgery and reduce the chance of the cancer coming back afterward.
This study tests a new immunotherapy drug (tislelizumab) combined with chemotherapy before either surgery or radiation for esophageal cancer. The goal is to see if this combination helps shrink the tumor and improves outcomes, and it may offer a promising option for patients who meet the criteria.
This trial tests a new combination of drugs for people with esophageal squamous cell carcinoma that is advanced or has spread. The goal is to see if the combination can help shrink tumors or slow the disease.
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug called adebrelimab before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes for people with locally advanced disease.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
Hear when a new Esophagus Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.